Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat cancers and other diseases, today announced two presentations highlighting results from recent preclinical research for Zymeworks’ antibody-drug conjugate candidates ZW220 and ZW251. Results will be presented at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference in Barcelona being held October 23-25, 2024.

'We are excited to share results from our preclinical studies, which highlight the activity of ZW220 in models of non-small cell lung, ovarian, and uterine cancers, as well as ZW251 in hepatocellular carcinoma models, both of which leverage our novel proprietary payload, ZD06519,' said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. 'We are encouraged by the progress of these next-generation ADC programs, which remain on track for IND filings in 2025, following the recent advancement of ZW171 and ZW191, which are currently recruiting for Phase 1 studies.”

Oral Presentation Details:

Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
Session Title: Proffered Papers: New Drugs on the Horizon
Date: Friday, October 25
Time: 12:00-12:12 pm Central European Summer Time (CEST)

Poster Presentation Details:

Title: ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
Session Title: Antibody-Drug Conjugates
Presentation number: PB165

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to anticipated preclinical data presentations; the timing and status of ongoing and future studies and the release of data; expectations regarding future regulatory filings and approvals and the timing thereof; the timing of and results of interactions with regulators; anticipated regulatory submissions and the timing thereof; Zymeworks’ preclinical pipeline; the anticipated benefits of the collaboration agreements with Jazz and BeiGene; the commercial potential of technology platforms and product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; the potential addressable market of zanidatamab; potential safety profile and therapeutic effects of zanidatamab and Zymeworks’ other product candidates; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com 

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com


Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

THỦ THUẬT HAY

Chuyển file từ điện thoại lên máy tính mà không cần cáp kết nối hoặc sử dụng Bluetooth

Vậy nên những phần mềm hỗ trợ chuyển dữ liệu lúc này sẽ phát huy được tác dụng của mình, SHAREIt là một trong những phần mềm thường được sử dụng để chuyển dữ liệu từ máy tính qua điện thoại và ngược lại, không chỉ cung

Cách đăng ký 4G Viettel 1 ngày 5k để có ngay 1GB Data tốc độ cao

Bạn đang cần một gói Data 4G Viettel dung lượng ổn để sử dụng cho một ngày? Đây là cách đăng ký 4G Viettel 1 ngày 5k để có ngay 1GB Data tốc độ cao truy cập Internet...

File APK là gì? Hướng dẫn cài tệp APK cho điện thoại Android từ Modradar

Ngoài cài đặt ứng dụng từ CH-Play, Android còn cung cấp cho người dùng tính năng tải và cài đặt ứng dụng trả phí 0 đồng từ file APK, giúp người dùng trải nghiệm những dịch vụ tốt nhất.

2 cách nhanh chóng giúp kiểm tra tình trạng chuyến bay trên iPhone

Bạn chuẩn bị đi du lịch hay là người thường xuyên 'du hí' đây đó trên những chuyến bay? Nếu bạn muốn kiểm tra tình trạng chuyến bay của mình trên iPhone thì hãy thực hiện ngay các bước dưới đây nhé!

Power Shade Pro - Hỗ trợ tùy biến thanh thông báo giống Android Pie

Khi bạn mở ứng dụng lần đầu tiên, bạn sẽ thấy một thanh trượt màu đen có dòng chữ Not running và 4 icon với nhiều chức năng. Đầu tiên bạn hãy trượt sang phải để bật Power Shade, rồi cung cấp các quyền cần thiết để chạy

ĐÁNH GIÁ NHANH

Giá 269,9 triệu đồng, Triumph Trident 660 có gì đáng để người mới chơi mô tô lựa chọn?

Triumph Trident 660 là mẫu xe entry-level của hãng xe Anh Quốc, sở hữu thiết kế tân hoài cổ cùng nhiều trang bị hiện đại. Xe có cảm giác vận hành thú vị phù hợp với người mới chơi.

Đánh giá xe Audi Q3 2019 về thiết kế nội ngoại thất và thông số kỹ thuật

Audi Q3 2019 là dòng xe nằm trong phân khúc xe SUV hạng sang cỡ nhỏ, xe sở hữu kích thước nhỏ gọn giúp linh hoạt trong đường phố đông đúc nhưng vẫn đáp ứng tốt không gian sử dụng cho gia đình nhỏ. Sức mạnh vận hành từ

Canon 800D vs Canon M6: "gà nhà" đá nhau

Cùng được một “mẹ” Canon xuất xưởng nhưng 800D là model DSLR trong khi M6 lại là mirrorless. Tuy nhiên, sự khác biệt về ngoại hình không làm cho M6 lép vế so với 800D. Cả hai đều là những con át chủ bài được hãng tung